Pediatric TTP: Two Distinct Forms Require Different Treatment Approaches

Thrombotic thrombocytopenic purpura (TTP) represents a critical pediatric emergency that, despite being first described 100 years ago in a teenage patient, remains poorly understood in children. This comprehensive review distinguishes between two fundamentally different forms of the disease that require distinct therapeutic approaches.

The pathophysiology centers on deficiency of ADAMTS13, an enzyme that normally cleaves von Willebrand factor multimers. Without this enzyme, ultra-large multimers accumulate, causing excessive platelet aggregation and widespread microthrombi formation. Congenital TTP (cTTP) results from inherited mutations in the ADAMTS13 gene, with over 200 mutations identified across different populations. The immune-mediated form (iTTP) involves autoantibodies that neutralize or deplete the enzyme.

Congenital TTP typically manifests in early childhood, often presenting as severe neonatal jaundice requiring exchange transfusion. The disease shows remarkable clinical heterogeneity, with some patients experiencing frequent episodes requiring monthly plasma therapy while others have prolonged remissions. Specific mutations like c.4143_4144dupA are common in European populations, while Asian populations show distinct mutation patterns. Triggers include infections, vaccinations, surgery, and pregnancy.

Diagnosis requires high clinical suspicion as symptoms can be subtle, particularly isolated thrombocytopenia in childhood. The classic pentad of symptoms (thrombocytopenia, hemolytic anemia, neurological symptoms, fever, and renal dysfunction) is rarely complete. Laboratory findings include severe ADAMTS13 deficiency (<10% activity), schistocytes on blood smear, and elevated lactate dehydrogenase.

Treatment has evolved significantly with therapeutic plasma exchange remaining the cornerstone therapy, supplemented by immunosuppression for iTTP cases. The recent approval of caplacizumab, a nanobody targeting von Willebrand factor, represents a major therapeutic advance. For cTTP, regular plasma infusions or prophylactic therapy may be necessary, while iTTP typically responds to immunosuppressive protocols.

Early recognition and appropriate treatment have dramatically improved outcomes, though the rarity of pediatric cases continues to challenge diagnosis and management. Understanding the distinct pathophysiology of each form is crucial for optimal therapeutic selection and long-term management strategies.